These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1390 related items for PubMed ID: 22075171

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Efficacy, immunogenicity and safety of the AS04-HPV-16/18 vaccine in Chinese women aged 18-25 years: End-of-study results from a phase II/III, randomised, controlled trial.
    Zhu FC, Hu SY, Hong Y, Hu YM, Zhang X, Zhang YJ, Pan QJ, Zhang WH, Zhao FH, Zhang CF, Yang X, Yu JX, Zhu J, Zhu Y, Chen F, Zhang Q, Wang H, Wang C, Bi J, Xue S, Shen L, Zhang YS, He Y, Tang H, Karkada N, Suryakiran P, Bi D, Struyf F.
    Cancer Med; 2019 Oct; 8(14):6195-6211. PubMed ID: 31305011
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention.
    Schwarz TF.
    Expert Rev Vaccines; 2008 Dec; 7(10):1465-73. PubMed ID: 19053203
    [Abstract] [Full Text] [Related]

  • 27. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.
    Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, de Carvalho NS, Skinner SR, Harper DM, Hedrick JA, Jaisamrarn U, Limson GA, Dionne M, Quint W, Spiessens B, Peeters P, Struyf F, Wieting SL, Lehtinen MO, Dubin G, HPV PATRICIA study group.
    Lancet; 2007 Jun 30; 369(9580):2161-2170. PubMed ID: 17602732
    [Abstract] [Full Text] [Related]

  • 28. Success of HPV vaccination is now a matter of coverage.
    Schiffman M, Wacholder S.
    Lancet Oncol; 2012 Jan 30; 13(1):10-2. PubMed ID: 22075169
    [No Abstract] [Full Text] [Related]

  • 29. Spotlight on AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®).
    McKeage K, Romanowski B.
    BioDrugs; 2011 Aug 01; 25(4):265-9. PubMed ID: 21815703
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomized controlled trial.
    Zhu FC, Chen W, Hu YM, Hong Y, Li J, Zhang X, Zhang YJ, Pan QJ, Zhao FH, Yu JX, Zhang YS, Yang X, Zhang CF, Tang H, Zhang H, Lebacq M, David MP, Datta SK, Struyf F, Bi D, Descamps D, HPV-039 study group.
    Int J Cancer; 2014 Dec 01; 135(11):2612-22. PubMed ID: 24740596
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008-2015.
    Cleveland AA, Gargano JW, Park IU, Griffin MR, Niccolai LM, Powell M, Bennett NM, Saadeh K, Pemmaraju M, Higgins K, Ehlers S, Scahill M, Johnson Jones ML, Querec T, Markowitz LE, Unger ER, HPV-IMPACT Working Group.
    Int J Cancer; 2020 Feb 01; 146(3):810-818. PubMed ID: 30980692
    [Abstract] [Full Text] [Related]

  • 36. Effect of different human papillomavirus serological and DNA criteria on vaccine efficacy estimates.
    Lang Kuhs KA, Porras C, Schiller JT, Rodriguez AC, Schiffman M, Gonzalez P, Wacholder S, Ghosh A, Li Y, Lowy DR, Kreimer AR, Poncelet S, Schussler J, Quint W, van Doorn LJ, Sherman ME, Sidawy M, Herrero R, Hildesheim A, Safaeian M, Costa Rica Vaccine Trial Group.
    Am J Epidemiol; 2014 Sep 15; 180(6):599-607. PubMed ID: 25139208
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Efficacy of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: interim analysis of a phase 2 double-blind, randomized, controlled trial.
    Konno R, Tamura S, Dobbelaere K, Yoshikawa H.
    Int J Gynecol Cancer; 2010 Apr 15; 20(3):404-10. PubMed ID: 20375805
    [Abstract] [Full Text] [Related]

  • 40. Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study.
    Romanowski B, Schwarz TF, Ferguson L, Peters K, Dionne M, Behre U, Schulze K, Hillemanns P, Suryakiran P, Thomas F, Struyf F.
    Hum Vaccin Immunother; 2016 Apr 15; 12(1):20-9. PubMed ID: 26176261
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 70.